People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2020 |
| TORL Biotherapeutics LLC | — | Pharmaceuticals | Series D+ | $158.3M | $1.8B | 2024 |
| AI Proteins, Inc. | — | Biotechnology | Series A | $24.6M | $30.0M | 2023 |
Mark Alles at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Alles on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Amir Nashat | 1 | 14 |
| Srinivas Akkaraju | 1 | 10 |
| Drew Dennison | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Bruce Evans | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Marc A. Cohen | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Stephane Bancel | 1 | 4 |
| Jorge Conde | 1 | 4 |
| David Licata | 1 | 4 |
| Robert E. Nelsen | 1 | 3 |
| Julia A. Novina | 1 | 3 |
| Carl A. Novina | 1 | 3 |
| James E. Bradner | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Mark Attanasio | 1 | 3 |
| Neil ` O'Brien | 1 | 3 |
| Elena A. Prokupets | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.